Aquestive Therapeutics, Inc. 8-K

What Happened

• Aquestive Therapeutics, Inc. filed a Current Report on Form 8-K on February 26, 2026, disclosing that it furnished a corporate investor presentation to be used in meetings with institutional investors, analysts and others. The presentation is provided under Regulation FD and is attached as Exhibit 99.1 to the filing. The report was signed by CFO A. Ernest Toth, Jr.

Key Details

• Filing date: February 26, 2026 (Form 8-K).
• Disclosure type: Regulation FD disclosure (Item 7.01) — investor presentation furnished to the public.
• Exhibit: 99.1 — Aquestive Therapeutics, Inc. Corporate Presentation dated February 2026.
• Signed by: A. Ernest Toth, Jr., Chief Financial Officer.

Why It Matters

• The filing makes the company’s current investor presentation publicly available, ensuring broader, compliant distribution of corporate information to the market.
• This 8-K does not report earnings, a transaction, or executive changes; it simply furnishes presentation materials that may contain strategic, operational or pipeline updates for investors to review.
• Investors should review the attached presentation for any updated guidance, strategic priorities or product/pipeline details, and monitor for any follow-up filings that amend or expand on the information.